Exasol Rated Best-in-Class Across 10 Measures in Dresner’s ADI Report 2021
9.2.2021 12:00:00 EET | Business Wire | Press release
For the fourth consecutive year, Exasol, the analytics database, has been named a customer experience and a vendor credibility Overall Leader in the Dresner Advisory Services Wisdom of Crowds® 2021 Analytical Data Infrastructure (ADI) Report. Exasol also achieved a perfect recommend score again - 100% of Exasol’s customers who participated in the report would recommend its analytics database. High placement in the upper-right quadrant confirms that customers receive high value and have strong confidence in Exasol.
In addition, Exasol was also ranked best-in-class for ten different measures, including reliability of technology, technical support and responsiveness, and integrity.
The Dresner 2021 ADI Market Study provides a detailed picture of perceptions, intentions, and realities associated with ADI platform choices. The report examines market preferences for ADI platforms including deployment and licensing priorities, data types, data modeling/management of data associated with ADI, and data preparation and loading priorities. It also covers leading choices in ADI development and deployment, as well as ADI interfaces and analytical features.
“We congratulate Exasol on maintaining a perfect recommend score for the fourth consecutive year from customers and receiving best-in-class in ten customer value measurement categories – demonstrating the value its customers perceive with its platform,” Howard Dresner, founder and chief research officer at Dresner Advisory Services. “Business and IT leaders require robust analytical data infrastructure systems more than ever to deliver business value during these unprecedented times.”
According to the Dresner ADI report, business intelligence (BI) related use cases—business reporting and dashboards, specifically—ranked as the top priority for ADI platforms. The appetite for traditional BI use cases continues to increase, as performance ranked as the highest priority for ADI platforms in 2021. Additionally, in-memory data capabilities are an important priority for more than 50% of respondents, and columnar data models surpass row-format based models for organizing analytical data.
The report also found that the majority of business functions prefer a cloud deployment versus on-premise software, but on-prem isn’t going away any time soon. It is still a priority for 40% of organizations. According to the report, respondents’ preferences are dictated by use cases, with some being more suited to cloud services and others to on-prem deployments. As a result, multiple buying centres are working with hybrid deployment models for ADI platforms, a preference that increases with company size.
“As a customer-obsessed organization, it is validation of our day-to-day work that our customers rate us so highly,” said Aaron Auld, CEO at Exasol. “Maintaining a perfect recommend score for the fourth consecutive year is as much as we can hope for and the least which we expect of ourselves. I’m incredibly proud of the Exasol team and the way they put all their energy into helping our customers on their analytics journey. Our outstanding results in the Dresner report are testament to that.”
To read the full report, visit our Dresner ADI 2021 page.
ENDS
About Exasol
The Exasol high-performance analytics database is built to run faster than any other database, delivering next-level performance, scale and ease of use. Analyze billions of rows in seconds; run high-performance analytics securely in the cloud or on-premise; deliver frictionless analytics with self-indexing that automatically tunes performance; and scale out analytics for one transparent price.
To learn more, please visit: www.exasol.com
About Dresner Advisory Services, LLC
Dresner Advisory Services was formed by Howard Dresner, an independent analyst, author, lecturer, and business adviser. Dresner Advisory Services, LLC focuses on creating and sharing thought leadership for Business Intelligence (BI) and related areas.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005090/en/
Contact information
PR contact
Carla Gutierrez, Head of Global Communications, Exasol
Email: Carla.gutierrez@exasol.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom